Aimmune Therapeutics, Inc. (AIMT) Given Average Rating of “Buy” by Brokerages
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $36.25.
Several equities analysts have commented on AIMT shares. ValuEngine downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 27th. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 20th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, March 22nd.
In other news, CFO Eric Bjerkholt bought 5,000 shares of the stock in a transaction on Friday, May 12th. The stock was acquired at an average cost of $19.84 per share, for a total transaction of $99,200.00. Following the acquisition, the chief financial officer now owns 5,000 shares of the company’s stock, valued at $99,200. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mary M. Rozenman sold 14,940 shares of the company’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $21.44, for a total value of $320,313.60. Following the completion of the sale, the insider now owns 9,103 shares of the company’s stock, valued at $195,168.32. The disclosure for this sale can be found here. Insiders sold a total of 125,000 shares of company stock valued at $2,574,179 over the last quarter. Company insiders own 24.56% of the company’s stock.
Several large investors have recently modified their holdings of AIMT. Russell Investments Group Ltd. bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $1,711,000. State Street Corp boosted its stake in shares of Aimmune Therapeutics by 50.5% in the fourth quarter. State Street Corp now owns 576,147 shares of the biotechnology company’s stock worth $11,782,000 after buying an additional 193,272 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $2,100,000. Norges Bank bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $1,258,000. Finally, Teachers Advisors LLC boosted its stake in shares of Aimmune Therapeutics by 2.4% in the fourth quarter. Teachers Advisors LLC now owns 43,229 shares of the biotechnology company’s stock worth $884,000 after buying an additional 1,025 shares during the period. Hedge funds and other institutional investors own 69.64% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics, Inc. (AIMT) Given Average Rating of “Buy” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/18/aimmune-therapeutics-inc-aimt-given-average-rating-of-buy-by-brokerages-2.html.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at 21.93 on Tuesday. The company has a 50-day moving average price of $18.53 and a 200-day moving average price of $19.95. Aimmune Therapeutics has a 52 week low of $10.27 and a 52 week high of $27.31. The stock’s market cap is $1.10 billion.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.05. Equities analysts anticipate that Aimmune Therapeutics will post ($2.66) EPS for the current year.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.